Literature DB >> 26315340

Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).

Cécile-Audrey Durel1, Julien Berthiller2, Silvia Caboni3, David Jayne4, Jacques Ninet1, Arnaud Hot1.   

Abstract

OBJECTIVE: To assess the long-term outcome in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA).
METHODS: A total of 101 patients fulfilling the American College of Rheumatology criteria for EGPA were included between 1990 and 2011. Clinical features, antineutrophil cytoplasm autoantibodies (ANCAs), and Five-Factors Score (FFS) were assessed at diagnosis. Overall and cumulative survival rates, relapse-free survival, and sequelae were studied based on ANCA status and FFS.
RESULTS: The rate of cardiomyopathy did not differ according to ANCA status. A total of 79.6% of patients achieved first remission, but 81.1% relapsed. ANCA-positive patients did not relapse more frequently but exhibited more severe disease with mononeuritis (P = 0.0004) and renal involvement (P = 0.02). Being Italian was the only prognostic factor associated with a higher relapse-free survival (P = 0.01), thanks to a longer maintenance of immunosuppressive drugs, suggesting the need for prolonged low-dose corticosteroids. Overall, survival reached 93.1% after a median followup of 6 years. No factor was associated with mortality, but patients over age 65 years with cardiomyopathy or ANCA positivity had more serious outcomes. Sequelae affected 83.2% of patients. Ear, nose, and throat (ENT) involvement was a protective factor for renal (P = 0.04) and cardiac (P = 0.03) morbidity. ANCA positivity was correlated with chronic kidney disease (P = 0.03) and chronic neurologic disability (P = 0.02).
CONCLUSION: The actual challenges of EGPA management concern morbidity prevention and quality of life improvement. Long-term corticosteroid treatment appears to reduce relapse risk. ENT involvement is associated with less renal and cardiac morbidity. ANCA positivity predicts renal and neurologic damage.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26315340     DOI: 10.1002/acr.22686

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  15 in total

1.  Eosinophilic Granulomatosis with Polyangiitis Presenting as Unilateral Acute Anterior Ischaemic Optic Neuropathy.

Authors:  Anthony Fong; Shahzada Ahmed; Satheesh Ramalingam; Rachel M Brown; Lorraine Harper; Susan P Mollan
Journal:  Neuroophthalmology       Date:  2020-06-25

Review 2.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

3.  The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.

Authors:  Alvise Berti; Divi Cornec; Cynthia S Crowson; Ulrich Specks; Eric L Matteson
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

4.  Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.

Authors:  Irena Doubelt; David Cuthbertson; Simon Carette; Sharon A Chung; Lindsy J Forbess; Nader A Khalidi; Curry L Koening; Carol Langford; Carol A McAlear; Larry W Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Robert F Spiera; Jason M Springer; Antoine G Sreih; Kenneth J Warrington; Peter A Merkel; Christian Pagnoux
Journal:  ACR Open Rheumatol       Date:  2021-05-25

5.  Eosinophilic granulomatosis with polyangiitis: myocardial thickening reversed by corticosteroids.

Authors:  Gustav Mattsson; Peter Magnusson
Journal:  BMC Cardiovasc Disord       Date:  2017-12-20       Impact factor: 2.298

6.  C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis.

Authors:  Jae Seung Moon; Sung Soo Ahn; Yong Beom Park; Sang Kyou Lee; Sang Won Lee
Journal:  Yonsei Med J       Date:  2018-09       Impact factor: 2.759

7.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

Authors:  Vítor Teixeira; Aladdin J Mohammad; Rachel B Jones; Rona Smith; David Jayne
Journal:  RMD Open       Date:  2019-06-05

Review 8.  Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology.

Authors:  Filippo Fagni; Federica Bello; Giacomo Emmi
Journal:  Front Med (Lausanne)       Date:  2021-02-24

Review 9.  Clinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue Diseases.

Authors:  Tsuyoshi Kasama; Airi Maeoka; Nao Oguro
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2016-01-18

10.  Gastrointestinal involvement in patients with vasculitis: IgA vasculitis and eosinophilic granulomatosis with polyangiitis.

Authors:  Keisuke Kawasaki; Shotaro Nakamura; Motohiro Esaki; Koichi Kurahara; Makoto Eizuka; Yasuharu Okamoto; Takashi Hirata; Minako Hirahashi; Yumi Oshiro; Shunichi Yanai; Kunihiko Sato; Yosuke Toya; Makoto Maemondo; Yasuo Terayama; Tamotsu Sugai; Takayuki Matsumoto
Journal:  Endosc Int Open       Date:  2019-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.